AgomAb Therapeutics NV (AGMB) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($433.4 million vs $422.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | EDIT |
|---|---|---|
| Share price | $8.80 | $2.75 |
| Market cap | $433.38M | $422.35M |
| 1-day change | -0.45% | +0.73% |
| 5-year return | — | -92.77% |
| EPS (TTM) | $-2.08 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $4.54 |
| 52-week low | $7.97 | $1.66 |
| Distance from 52-week high | -50.62% | -39.39% |
| Average volume | 135.61K | 2.48M |
| Shares outstanding | 49.25M | 153.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AGMB vs EDIT FAQ
Which is bigger, AgomAb Therapeutics NV or Editas Medicine?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $433.38M compared with $422.35M for Editas Medicine (EDIT).
Are AgomAb Therapeutics NV and Editas Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.